Posts by Jeremy Neil Ruskin, MD
-
Study: Inhaled Flecainide Converts Atrial Fibrillation
An experimental formulation of inhaled flecainide acetate shows promise for reducing hospital admissions for atrial fibrillation and minimizing flecainide side effects.
-
Mortality From Infective Endocarditis Related to Cardiovascular Implantable Electronic Devices Declining in U.S.
In a nationwide study, researchers from the Corrigan Minehan Heart Center at Massachusetts General Hospital found in-hospital mortality from infective endocarditis related to cardiovascular implantable electronic devices decreased over a 15-year period, even though the number of comorbidities per patient increased.
-
Cause of Myocardial Injury Affects Mortality Risk in Patients Hospitalized With COVID-19
Jeremy N. Ruskin, MD, and colleagues found that high-sensitivity troponin T elevation from any cause is a strong predictor of mortality in patients hospitalized with COVID-19, but the odds ratio for patients with elevation due to a primary cardiac etiology was 4.6 compared with 2.7 for patients without.
-
Pilot: Mind–Body Interventions Enhance Coping by Patients with Paroxysmal Atrial Fibrillation
Massachusetts General Hospital researchers found in a pilot randomized, waitlist-controlled trial that the SMART Program (an eight-week group-based, virtually delivered mind–body intervention) improved quality of life, and stress reactivity/coping, and had positive effects in paroxysmal atrial fibrillation patients.
-
Watchman Device: Death, Stroke and Device Embolization Can Occur Well After Implantation
Cardiologists at Massachusetts General Hospital have gathered real-world data on adverse events related to the implantation of the original Watchman left atrial appendage closure device, including events that occurred a year or more after the implant procedure.
-
Application of Bioadhesive to Heart Improves Survival in Preclinical Model of Myocardial Infarction
Telemachus & Irene Demoulas Family Foundation Center for Cardiac Arrhythmias researchers have formulated a gelatin-based bioadhesive that can be applied in liquid form to the site of myocardial infarction, then polymerized with visible-spectrum light, rapidly creating a firm but flexible scaffold to support weakened tissue and preserve left ventricular function.
-
Smartphone App Has Potential to Detect AFib In Patients with Known History
A smartphone application under development shows promise for accurately discriminating atrial fibrillation from sinus rhythm in patients with a previous history of atrial fibrillation.
-
Very Low QRS Voltage in Single Frontal Lead Predicts Recurrence of Neurally Mediated Syncope
Patients with neurally mediated syncope who have very low QRS voltage in just one frontal-plane electrocardiography lead are at increased risk of experiencing recurrence of syncope, independently of clinical risk factors for recurrence.
Biography
Dr. Jeremy Ruskin is Founder and Director Emeritus of the Telemachus & Irene Demoulas Family Foundation Center for Cardiac Arrhythmias at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. He received his undergraduate degree from Tufts University and his medical degree from Harvard Medical School. He completed his residency in Internal Medicine at Beth Israel Hospital Boston and his fellowship in Cardiovascular Disease at Mass General. He received his training in clinical cardiac electrophysiology at the USPHS Hospital in Staten Island, New York under the mentorship of Dr. Anthony Damato.
In 1978, Dr. Ruskin founded the first cardiac arrhythmia service and clinical electrophysiology laboratory in New England and one of the first such services in the United States. As founder and director of the Mass General Fellowship Program in Clinical Cardiac Electrophysiology, he has been responsible for the training of more than 120 fellows in cardiac electrophysiology, many of whom are leaders in the field. His research focuses on new technologies for catheter ablation of atrial fibrillation, mechanisms and prevention of ventricular arrhythmias and sudden cardiac death, risk stratification for sudden death, and cardiac safety issues in new drug and device development. He is an author of more than 450 scientific publications. Dr. Ruskin is the recipient of the 1997 Michel Mirowski Award for Excellence in Clinical Cardiology and Electrophysiology and the 2002 Heart Rhythm Society Pioneer in Pacing and Electrophysiology Award. He holds the Omran Alomran Endowed Chair in Cardiology at Mass General. In 2017, the Jeremy Ruskin, MD and Dan Starks Endowed Chair in Cardiology was established at Mass General in recognition of Dr. Ruskin’s pioneering contributions to Mass General and the field of clinical cardiac electrophysiology. In 2018, Dr. Ruskin received the William Silen Lifetime Achievement in Mentoring Award at Harvard Medical School.